Skip to main content

Table 3 Multivariate analysis for virologic relapse after lamivudine cessation ( n = 116)

From: Clinical course of chronic hepatitis B patients who were off-treated after lamivudine treatment: analysis of 138 consecutive patients

HBeAg-positive patients (n = 83)

Univariate analysis

Multivariate analysis

 

HR

95% CI

P-value

HR

95% CI

P-value*

Age at cessation (<40 years)

0.511

0.260-1.005

0.042

0.520

0.264-0.998

0.048

Sex (male)

1.038

0.538-2.003

0.910

-

-

-

Liver cirrhosis, presence

0.923

0.283-3.010

0.894

-

-

-

HBV DNA (Log10copies/mL)+

0.875

0.657-1.166

0.362

-

-

-

HBeAg loss at LAM cessation

2.503

0.599-10.459

0.209

-

-

-

Treatment duration (months)

0.990

0.974-1.007

0.258

-

-

-

HBV DNA levels (<50 copies/mL)†

0.489

0.257-0.971

0.041

0.507

0.261-0.987

0.046

HBeAg-negative patients (n = 33)

HR

95% CI

P -value

HR

95% CI

P -value

Age at cessation (<40 years)

0.188

0.023-1.510

0.116

0.276

0.033-2.314

0.236

Sex (male)

0.478

0.099-2.307

0.478

-

-

-

Liver cirrhosis, presence

1.689

0.433-6.591

0.451

-

-

-

HBV DNA (Log10copies/mL) +

0.509

0.276-1.151

0.354

-

-

-

Treatment duration (months)

0.994

0.950-1.040

0.781

-

-

-

HBV DNA levels (<50 copies/mL)‡

0.145

0.038-0.552

0.005

0.186

0.048-0.723

0.015

  1. C.I, confidence interval; HR, hazard ratio; LAM, lamivudine.
  2. +Serum HBV DNA level at the initiation of lamivudine treatment.
  3. ‡Serum HBV DNA level at cessation of lamivudine treatment.
  4. * Cox Proportional Hazards model with a backward elimination method.
Back to article page

Virology Journal

ISSN: 1743-422X